Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone353-1438-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.56 billion
Profitability
Miscellaneous
Employees90,000
Next Earnings Date11/19/2019 (Estimated)
OptionableOptionable
Medtronic (NYSE:MDT) Frequently Asked Questions
What is Medtronic's stock symbol?
Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."
How often does Medtronic pay dividends? What is the dividend yield for Medtronic?
Medtronic announced a quarterly dividend on Friday, August 23rd. Investors of record on Friday, September 27th will be given a dividend of $0.54 per share on Friday, October 18th. This represents a $2.16 annualized dividend and a dividend yield of 2.03%. The ex-dividend date of this dividend is Thursday, September 26th. View Medtronic's Dividend History.
How were Medtronic's earnings last quarter?
Medtronic PLC (NYSE:MDT) issued its earnings results on Tuesday, August, 20th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.18 by $0.08. The medical technology company had revenue of $7.49 billion for the quarter, compared to the consensus estimate of $7.40 billion. Medtronic had a return on equity of 14.36% and a net margin of 14.41%. The firm's revenue for the quarter was up 1.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.17 earnings per share. View Medtronic's Earnings History.
When is Medtronic's next earnings date?
What guidance has Medtronic issued on next quarter's earnings?
Medtronic issued an update on its FY 2020 earnings guidance on Tuesday, August, 20th. The company provided earnings per share guidance of $5.54-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.48.
What price target have analysts set for MDT?
18 brokerages have issued 12-month target prices for Medtronic's shares. Their forecasts range from $100.00 to $133.00. On average, they anticipate Medtronic's stock price to reach $114.33 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price. View Analyst Price Targets for Medtronic.
What is the consensus analysts' recommendation for Medtronic?
18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.
What are Wall Street analysts saying about Medtronic stock?
Here are some recent quotes from research analysts about Medtronic stock:
- 1. Northland Securities analysts commented, "We continue to wait for a definitive breakout in key categories in terms of growth. In fairness, Medtronic continues to improve operational efficiencies." (8/21/2019)
- 2. Needham & Company LLC analysts commented, "Market open, Ellex announced preliminary FY19 revenue below our expectations and IFRS EBITDA slightly narrower than our expectations. iTrack, 2RT and Tango lasers delivered FY19 y/y revenue growth, but overall growth was below our estimates. Ellex announced the appointment of Maria Maieli, current CFO, as Interim CEO. Ellex expects to release final F2H19 results on August 29, 2019." (7/23/2019)
- 3. According to Zacks Investment Research, "The declining CRHF segment raises concern for Medtronic. Escalating costs and expenses continue to weigh on Medtronic’s bottom line. On a positve note, in the past year, shares of Medtronic outperformed its industry. The company is successfully registering sustainable growth across major groups and regions, in addition to displaying successful achievement of synergy targets. The company is focusing on geographical diversification of its businesses. This apart, the company has been seeing certain favorable developments in its Diabetes business. The updated 2019 guidance with raised EPS view increases investors’ confidence on the stock. Meanwhile, we are optimistic about the recently-closed acquisition of Mazor Robotics which is expected to fortify Medtronic's position in spine surgery." (5/20/2019)
- 4. Barclays PLC analysts commented, "We now project $5.15 versus $5.12 consensus. Formal FY20 guidance will come in May but mgmt expressed comfort with the Street EPS estimate (per Refinitiv $5.44) which implies ~5.6% y/y growth off the revised mid- point for FY19. In Jan, mgmt said a higher tax rate could prompt EPS growth to be up to 250bp below its 8% long-range plan (LRP) CAGR target. Mgmt noted it is still working through its options for financial engineering. We think FY20 is likely a back- end loaded year given revenue cadence considerations (i.e. comps, new products launches) as well as FX impacts. We now est. $5.42 vs. $5.38 prior. Net/net, nothing materially changed our view. We think the valuation offers some upside and we rate MDT OW. That said, the upside case may take time to work out as execution confidence builds and many pipeline milestones are more 2020 events." (2/20/2019)
Has Medtronic been receiving favorable news coverage?
News articles about MDT stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Medtronic earned a news impact score of 0.8 on InfoTrie's scale. They also gave news articles about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Medtronic.
Who are some of Medtronic's key competitors?
Some companies that are related to Medtronic include Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), Hologic (HOLX), Steris (STE), Varian Medical Systems (VAR) and Insulet (PODD).
What other stocks do shareholders of Medtronic own?
Who are Medtronic's key executives?
Medtronic's management team includes the folowing people:
- Mr. Omar S. Ishrak, Chairman & CEO (Age 63)
- Ms. Karen L. Parkhill, Exec. VP, CFO & Principal Accounting Officer (Age 54)
- Mr. Bradley E. Lerman, Sr. VP, Gen. Counsel & Company Sec. (Age 61)
- Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 57)
- Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 58)
Who are Medtronic's major shareholders?
Medtronic's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Manning & Napier Group LLC (0.23%), CIBC Private Wealth Group LLC (0.19%), Envestnet Asset Management Inc. (0.12%), Strs Ohio (0.10%), Hexavest Inc. (0.07%) and Calamos Advisors LLC (0.06%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Karen L Parkhill, Michael J Coyle, Omar Ishrak, Richard H Anderson and Richard Kuntz. View Institutional Ownership Trends for Medtronic.
Which institutional investors are selling Medtronic stock?
MDT stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Manning & Napier Group LLC, PGGM Investments, Gateway Investment Advisers LLC, Hexavest Inc., Strs Ohio, Riverbridge Partners LLC and Artemis Investment Management LLP. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Carol A Surface, Geoffrey Martha, Hoedt Rob Ten, Hooman Hakami and Richard Kuntz. View Insider Buying and Selling for Medtronic.
Which institutional investors are buying Medtronic stock?
MDT stock was purchased by a variety of institutional investors in the last quarter, including Sabal Trust CO, Community Trust & Investment Co., Ferguson Wellman Capital Management Inc., Varma Mutual Pension Insurance Co, Assenagon Asset Management S.A., State of Alaska Department of Revenue, Stock Yards Bank & Trust Co. and Randolph Co Inc. Company insiders that have bought Medtronic stock in the last two years include Karen L Parkhill, Omar Ishrak and Richard H Anderson. View Insider Buying and Selling for Medtronic.
How do I buy shares of Medtronic?
Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Medtronic's stock price today?
One share of MDT stock can currently be purchased for approximately $106.62.
How big of a company is Medtronic?
Medtronic has a market capitalization of $143.05 billion and generates $30.56 billion in revenue each year. The medical technology company earns $4.63 billion in net income (profit) each year or $5.22 on an earnings per share basis. Medtronic employs 90,000 workers across the globe.View Additional Information About Medtronic.
What is Medtronic's official website?
How can I contact Medtronic?
Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]
MarketBeat Community Rating for Medtronic (NYSE MDT)
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
